Clinical Trial Update: Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma [Phase 2]

View source ↗

Summary

A Phase II trial of nivolumab plus ipilimumab in patients with Renal Medullary Carcinoma has been terminated, with the study status updated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Renal Medullary Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Kidney Medullary Carcinoma, Loss of INI 1 Protein Expression | Phase 2 | Status: TERMINATED